|
Polycystic Ovary Syndrome
|
0.300 |
Biomarker
|
disease |
CTD_human |
Progesterone-regulated genes, including mitogen-inducible gene 6 (MIG6), leukemia inhibitory factor (LIF), GRB2-associated binding protein 1 (GAB1), S100P, and claudin-4 were significantly lower in PCOS endometrium; whereas cell proliferation genes, such as Anillin and cyclin B1, were up-regulated.
|
21411543 |
2011 |
|
Sclerocystic Ovaries
|
0.300 |
Biomarker
|
disease |
CTD_human |
Progesterone resistance in PCOS endometrium: a microarray analysis in clomiphene citrate-treated and artificial menstrual cycles.
|
21411543 |
2011 |
|
Pancreatic Neoplasm
|
0.040 |
AlteredExpression
|
disease |
LHGDN |
The role of S100P in the invasion of pancreatic cancer cells is mediated through cytoskeletal changes and regulation of cathepsin D.
|
17875703 |
2007 |
|
Pancreatic Neoplasm
|
0.040 |
Biomarker
|
disease |
LHGDN |
S100P is an early developmental marker of pancreatic carcinogenesis.
|
17000674 |
2006 |
|
Pancreatic Neoplasm
|
0.040 |
Biomarker
|
disease |
LHGDN |
S100P promotes pancreatic cancer growth, survival, and invasion.
|
16061848 |
2005 |
|
Pancreatic Neoplasm
|
0.040 |
PosttranslationalModification
|
disease |
LHGDN |
Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling.
|
14716296 |
2004 |
|
Adenocarcinoma
|
0.030 |
Biomarker
|
group |
LHGDN |
Molecular regulation of S100P in human lung adenocarcinomas.
|
18575778 |
2008 |
|
Adenocarcinoma
|
0.030 |
Biomarker
|
group |
LHGDN |
Diagnostic utility of S100P and von Hippel-Lindau gene product (pVHL) in pancreatic adenocarcinoma-with implication of their roles in early tumorigenesis.
|
18162774 |
2008 |
|
Adenocarcinoma
|
0.030 |
Biomarker
|
group |
LHGDN |
Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer.
|
15632002 |
2005 |
|
Prostatic Neoplasms
|
0.020 |
AlteredExpression
|
group |
LHGDN |
Marked gene transcript level alterations occur early during radical prostatectomy.
|
17448597 |
2008 |
|
Prostatic Neoplasms
|
0.020 |
AlteredExpression
|
group |
LHGDN |
In our study, we evaluated the functional significance of S100P expression on prostate tumor growth in vitro and in vivo.
|
18452169 |
2008 |
|
Osteoporosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, the expression of carbonic anhydrase 1 (CA1) and S100 calcium‑binding protein P (S100P) in MIO was significantly different compared with senile OP, postmenopausal OP and NC samples.
|
29750314 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Four MMPs (MMP1, MMP7, MMP9 and MMP12), which were upregulated in lung AC, were clustered into one group with other genes, including NAD(P)H quinone oxidoreductase 1, claudin 3 (CLDN3), S100 calcium-binding protein P, serine protease inhibitor Kazal type 1, collagen type XI α 1 chain, periostin and desmoplakin (DSP), following cluster analysis.
|
29928392 |
2018 |
|
Malignant neoplasm of gastrointestinal tract
|
0.010 |
Biomarker
|
disease |
BEFREE |
Profiling for active enhancers using the H3K27ac histone modification revealed UC-derived organoid enrichment for pathways indicative of gastrointestinal cancer, including S100 calcium-binding protein P (<i>S100P</i>), and revealed novel markers for GI cancer, including both <i>LYZ</i> and neuropeptide S receptor 1 (<i>NPSR1</i>).
|
29983891 |
2018 |
|
Nasopharyngeal carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In the present study, the function of S100 calcium binding protein P (S100P) in the C666-1 nasopharyngeal carcinoma (NPC) cell line was examined.
|
28693201 |
2017 |
|
Early-Stage Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We demonstrated that a high S100Pn expression level was associated with poor survival in early stage breast cancer patients.
|
23364898 |
2013 |
|
ovarian neoplasm
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
Unfavourable prognostic significance of S100P expression in ovarian cancers.
|
17539915 |
2007 |